Edotreotide peptide is a selective ligand peptide that targets the somatostatin receptor 2 (SSTR2). It achieves precise diagnosis and treatment of tumors by binding to SSTR2 with high affinity. This peptide consists of 8 amino acids and contains a disulfide bond in its structure, which can form radiopharmaceuticals by chelating with radioactive isotopes (such as ⁶⁸Ga, ¹⁷⁷Lu, ⁹⁰Y). In diagnosis, ⁶⁸Ga-labeled Edotreotide is used for PET imaging to locate SSTR-positive neuroendocrine tumors (such as gastrointestinal and pancreatic NETs, lung and thymus NETs), and its tumor uptake rate is significantly higher than that of similar drugs, and it can reach an 80% tumor activity peak within 30 minutes. In the treatment field, ¹⁷⁷Lu-labeled Edotreotide induces tumor cell apoptosis by releasing β-rays, and clinical trials have shown that it has a strong targeted killing effect on neuroendocrine tumors such as metastatic carcinoid tumors, significantly prolonging the progression-free survival of patients, while minimizing damage to healthy tissues. It is a representative drug in peptide receptor radioisotope therapy (PRRT).
Our products form
Edotreotide COA
Edotreotide peptide plays a crucial role in the diagnosis of neuroendocrine tumors (NETs). It forms targeted imaging agents by binding to radioactive nuclides, enabling high-sensitivity, precise localization and staging assessment of SSTR-positive tumors. The following elaborates on its diagnostic application from multiple aspects:
Core Diagnostic Technology: Somatostatin Receptor Imaging (SRI)
The ⁶⁸Ga-edotreotide formed by the combination of edotreotide and gallium-68 (⁶⁸Ga) is the core reagent for PET/CT imaging. Its diagnostic value lies in:
High sensitivity and specificity
⁶⁸Ga-edotreotide has a 3-fold higher affinity for SSTR2 compared to traditional drugs (such as ⁶⁸Ga-DOTATOC), resulting in a significant increase in tumor uptake rate. It is particularly suitable for the detection of small lesions (such as metastases with a diameter of less than 5mm). Clinical data show that its detection rate for gastrointestinal pancreatic NETs (GEP-NETs) exceeds 90%, significantly outperforming conventional imaging methods such as CT/MRI.
Fast imaging and dynamic assessment
The tumor activity can reach 80% within 30 minutes after injection, reaching a peak at 70±20 minutes. The imaging time window is short, allowing for rapid completion of whole-body scans. Through dynamic imaging, the hemodynamic characteristics of the tumor can be evaluated, assisting in the differentiation between benign and malignant lesions.
Whole-body assessment and staging
A single injection can achieve whole-body tumor localization, clearly displaying the primary and metastatic lesions (such as liver, bone, and lymph node metastases), providing a key basis for tumor staging (such as the AJCC staging system). Studies have shown that ⁶⁸Ga-edotreotide imaging changes the initial staging of approximately 30% of patients, influencing treatment decisions.
Pre-treatment screening and prognosis prediction
By quantifying the expression level of SSTR (such as the SUVmax value), the efficacy of peptide receptor radionuclide therapy (PRRT) can be predicted. Patients with high SSTR expression have a significantly higher objective response rate (ORR) to ¹⁷⁷Lu-edotreotide treatment than those with low expression (21.9% vs. 4.2%).
Clinical application scenarios and advantages
Early diagnosis and asymptomatic tumor detection
Neuroendocrine tumors often have no specific symptoms in the early stage. ⁶⁸Ga-edotreotide imaging can detect tiny tumors in asymptomatic patients, enabling early intervention. For example, pancreatic NETs can be detected through imaging when the diameter is less than 2cm, and the 5-year survival rate significantly increases.
Differential diagnosis of difficult cases
For lesions that are difficult to clearly identify through conventional imaging (such as CT/MRI), ⁶⁸Ga-edotreotide imaging can assist in differentiating based on SSTR expression characteristics. For example, positive SSTR expression in lung nodules suggests a possibility of neuroendocrine tumors, while negative results are more likely to indicate lung cancer.
Treatment monitoring and follow-up
During PRRT or targeted therapy, ⁶⁸Ga-edotreotide imaging can dynamically assess changes in tumor metabolic activity, enabling early detection of treatment resistance or recurrence. Studies have shown that the time for imaging conversion from negative to positive is 3-6 months earlier than that of CT/MRI, providing a basis for adjusting treatment plans.
Special site tumor diagnosis
Meningioma: Some meningiomas express SSTR, ⁶⁸Ga-edotreotide imaging can assist in surgical planning, reducing postoperative residual.
Pediatric NETs: By adjusting the radiation dose, it can be safely used in pediatric patients, avoiding excessive radiation damage.
Multiple endocrine adenoma disease (MEN): It can simultaneously evaluate the tumor burden of multiple endocrine organs (such as the pancreas, parathyroid glands), simplifying the management process.
Comparison with traditional diagnostic methods
Compared with CT/MRI
Sensitivity: ⁶⁸Ga-edotreotide imaging has a significantly higher detection rate for small lesions than CT/MRI, especially for the detection of metastases in organs such as the liver and bones.
Specificity: Through SSTR expression characteristics, it can reduce false positive results from non-tumorous lesions (such as liver hemangiomas, bone islands).
Functional information: It provides information on tumor metabolic activity, assisting in differentiating between benign and malignant lesions and evaluating prognosis.
Compared with biomarker detection
Chromogranin A (CgA): Although it is a common serum biomarker for NETs, its sensitivity is only about 70%, and it is affected by drugs (such as proton pump inhibitors). ⁶⁸Ga-edotreotide imaging can make up for its shortcomings and achieve dual assessment of morphology and function.
Hormone level testing: For functional NETs (such as insulinoma and gastrinoma), hormone testing can assist in localization, but non-functional tumors need to rely on imaging techniques.
Research Frontiers and Technology Optimization
New indications exploration
Non-NETs applications: Studies have shown that some non-NETs such as breast cancer and renal cell carcinoma also express SSTR. ⁶⁸Ga-edotreotide imaging may expand its application scope.
α-ray nuclide imaging: For example, ²¹¹At-labeled Edotreotide, its α-ray tissue penetration depth is shorter, which may improve the detection sensitivity of small lesions.
Technology improvement
Dual receptor targeted imaging: Develop a complex that simultaneously targets SSTR2 and GLP-1R to increase tumor uptake rate and diagnostic specificity.
Nanotechnology: Combine Edotreotide with nanoparticles to enhance drug stability and tumor penetration ability, and improve imaging quality.
Artificial intelligence-assisted diagnosis
By analyzing the Ga-edotreotide imaging images using deep learning algorithms, the tumor burden can be automatically quantified, treatment responses can be predicted, and the diagnostic efficiency and accuracy can be improved.
Edotreotide peptide is a ligand peptide targeting the somatostatin receptor 2 (SSTR2). It demonstrates unique stability and safety characteristics in the treatment of neuroendocrine tumors (NETs). Its core advantages lie in the stability of the drug structure, the efficiency of targeted delivery, and the controllable management of side effects.
Drug Structural Stability: The Foundation for Long-Term Efficacy
The chemical structure of Edotreotide has been optimized and designed to possess high stability. Its core framework is composed of short-chain amino acids, which are synthesized using solid-phase or liquid-phase techniques, forming a stable disulfide bond structure (if multiple disulfide bonds are required, protecting groups such as trt, Acm, etc. are used to ensure the accuracy of synthesis). This structural stability ensures that Edotreotide is not easily hydrolyzed in the body, prolonging its half-life and maintaining an effective blood drug concentration. For example, in the clinical trials of gastrointestinal pancreatic neuroendocrine tumors (GEP-NETs), patients receive 177Lu-edotreotide treatment once every 3 months, achieving continuous tumor control and reducing the need for frequent administration.
In addition, the chelation process of Edotreotide with radioactive nuclides (such as 177Lu, 90Y, 68Ga) is mature, and the formed radioactive conjugates remain stable during storage and transportation. Studies have shown that 177Lu-edotreotide can be stored for 2 years at -80°C and 1 year at -20°C. After thawing, the solution maintains stability for 6 months, ensuring the reliability for clinical use.
Targeted Delivery Efficiency: Precise Killing and Low Off-target Toxicity
The high affinity of Edotreotide for SSTR2 (3 times higher than traditional drugs such as DOTATOC) is the key to its safety. By competitively binding to SSTR2, Edotreotide precisely delivers the radioactive nuclide to tumor cells. The β-rays (with a tissue penetration depth of approximately 2mm) directly induce tumor cell apoptosis while minimizing damage to the surrounding normal tissues. For example:
GEP-NETs treatment: In the COMPETE trial, the median progression-free survival (mPFS) of the 177Lu-edotreotide group reached 23.9 months, significantly longer than that of the everolimus group (14.1 months), and the incidence of treatment-related side effects was lower (82.5% vs 97%).
Treatment of lung and thymus NETs: The LEVEL trial showed that 177Lu-edotreotide may significantly prolong the mPFS of patients with lung cancer NET and thymic cancer (TC), and the incidence of serious side effects such as myelodysplastic syndrome (e.g., bone marrow suppression) was only 1 case (grade 2), much lower than that of traditional chemotherapy.
This "low-toxicity and high-efficiency" characteristic is attributed to the targeting property of Edotreotide: the absorbed dose in tumor tissues is high, while healthy tissues (such as kidneys) reduce radiation exposure through a renal protective amino acid solution, and the renal toxicity was reduced by 60% in the trial.
Controllable Side Effect Management: Enhancing Treatment Tolerance
The safety of Edotreotide has been verified in multiple clinical trials:
During the treatment with 177Lu-edotreotide, the incidence of grade 3-4 toxic events (such as neutropenia and thrombocytopenia) was less than 10%, and most were transient. These could be alleviated by dose adjustment or supportive treatment.
Common side effects included fatigue (30%-50%), nausea (20%-30%), and mild renal dysfunction (10%-15%). Most were grade 1-2 and did not require treatment interruption.
Long-term follow-up showed that 177Lu-edotreotide did not increase the risk of secondary malignancies (such as myelodysplastic syndrome, acute leukemia), and had a minor impact on quality of life (significant improvement in patient-reported fatigue and pain symptoms).
Special Populations and Long-term Safety
Children: By adjusting the radioactive dose (e.g., 1.59 MBq/kg per body weight), Edotreotide demonstrated good safety in the treatment of pediatric NETs and no serious long-term side effects were reported.
Patients with renal insufficiency: The renal protection protocol (such as amino acid infusion) significantly reduced the radiation dose to the kidneys, allowing patients with mild renal insufficiency to safely receive treatment.
Long-term treatment: In the COMPETE trial, 82.5% of patients completed 4 cycles of treatment, with significantly higher adherence than the everolimus group (with a high rate of 35% of patients discontinuing treatment due to side effects), indicating that Edotreotide is suitable for long-term use.
FAQ
1. What is the main function of Edotreotide peptide?
Edotreotide is a selective ligand peptide that targets the somatostatin receptor 2 (SSTR2). By binding to radioactive nuclides (such as ¹⁷⁷Lu, ⁶⁸Ga) to form radiolabeled conjugates, it enables targeted diagnosis and treatment of SSTR-positive tumors. Its core functions include:
Diagnosis: ⁶⁸Ga-edotreotide imaging can precisely locate neuroendocrine tumors (NETs), with a sensitivity exceeding 90%, significantly superior to CT/MRI.
Treatment: ¹⁷⁷Lu-edotreotide induces tumor cell apoptosis by releasing beta rays. Clinical trials have shown that it can significantly prolong the progression-free survival (PFS) of patients with lung and thymus NETs, and the side effects are controllable.
2. How stable is the edotreotide peptide?
The stability of edotreotide is reflected in two aspects: chemical structure and storage conditions.
Chemical structure: Its molecule contains disulfide bonds (Cys2-Cys7), which are synthesized using solid-phase or liquid-phase techniques to ensure structural stability. When combined with radioactive isotopes, the resulting complex (such as ¹⁷⁷Lu-edotreotide) remains stable during storage and transportation. For example, it can be stored for 2 years at -80°C, and the solution remains stable for 6 months after thawing.
Storage conditions: Powder form is recommended to be stored sealed at 2-8°C. Solution form should avoid repeated freezing and thawing to maintain activity.
3. How safe is Edotreotide peptide?
The safety of Edotreotide has been verified in clinical trials. Its advantages include:
Targeting: Precisely delivering radioactive nuclides through SSTR2 to minimize damage to normal tissues. For example, in the treatment with ¹⁷⁷Lu-edotreotide, the incidence of grade 3-4 hematological toxicities (such as neutropenia) is less than 10%, and most are transient.
Controllable side effects: Common side effects include fatigue and nausea (grade 1-2). Long-term follow-up has not increased the risk of secondary malignant tumors.
Applicability to special populations: Through dose adjustment (such as for children at 1.59 MBq/kg per kg of body weight), Edotreotide can be safely used in children and patients with renal insufficiency.
Hot Tags: edotreotide peptide, China edotreotide peptide manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, PT 141 Injection, glp1 shot, etelcalcetide structure
